A watershed panel at BioAsia 2026 revealed a transformation that has profound implications for global life sciences innovation: India’s Global Capability Centers (GCCs) are no longer primarily cost-optimization vehicles but have evolved into core contributors to worldwide R&D and digital transformation strategies. Executives from Novartis, Takeda, Amgen, Olympus, and Sanofi provided concrete evidence that Hyderabad, in particular, has emerged as an indispensable innovation hub where cutting-edge AI, behavioral science, and digital health capabilities are being developed for deployment in the world’s most sophisticated markets.
From “Outsourcing” to “Strategic Partnership”
For decades, India’s role in global pharmaceutical operations was characterized—often dismissively—as “back-office” functions: IT support, business process outsourcing, and routine data management. The cost arbitrage was compelling, the talent was available, but the work was largely viewed as non-strategic.
The BioAsia 2026 GCC panel documented a complete inversion of this narrative. Gail Horwood, Vice President and Head of Hyderabad Digital Center for Novartis, described her team as an “integrated extension of global teams,” emphasizing that the work being done in Hyderabad is not support for strategy developed elsewhere—it is the strategy.
“We are building large language model-based behavioral science tools that will be deployed in the United States market,” Horwood explained. “This is not adaptation of existing tools or localization of global platforms. This is original innovation, created in Hyderabad, for the world’s most demanding healthcare market.”
The significance of this statement cannot be overstated. Novartis, one of the world’s premier pharmaceutical companies, is entrusting its Hyderabad team with developing AI-driven patient engagement tools that span both physical and digital behavioral science touchpoints—capabilities that directly impact commercial success in its largest market.
From Cost Center to “Flagship Innovation Location”
Sanjay Patel, Site Head of Takeda’s Hyderabad GCC, reinforced this transformation narrative by describing the center’s evolution from a support function to what he termed a “flagship innovation location.” Takeda’s Hyderabad operation now leads global initiatives in:
- AI-driven drug discovery research: Computational chemistry and target identification using machine learning platforms
- Quality management systems: Developing global standards for manufacturing excellence and regulatory compliance
- Professional support functions: Not just executing strategies developed at headquarters but participating in strategy formation
Patel emphasized that this evolution reflects India’s growing “digital depth”—a term that encompasses not just technical skills but understanding of how digital capabilities integrate with scientific workflows, regulatory requirements, and commercial realities.
“The question companies now ask is not whether to have an India GCC, but how to maximize the strategic value of their India presence,” Patel stated. “Hyderabad has moved from being a preferred location to an indispensable partner.”
The Olympus Digital and R&D Strategy Pillar
The medical technology sector’s embrace of India’s GCC model was exemplified by Olympus Corporation’s presence on the panel. The company has positioned its India operations as a “digital and R&D strategy pillar”—a central engine for global product development and strategic decision-making.
For medical device companies, where hardware development, software integration, and regulatory compliance must be tightly coordinated, having an India center lead global R&D represents a significant vote of confidence in local capabilities. Olympus executives noted that the speed of iteration, quality of engineering talent, and cost-effectiveness of the Hyderabad ecosystem enable product development cycles that would be prohibitively expensive in traditional medical device hubs in Japan, Germany, or the United States.
The company’s India team is now involved in:
- Medical imaging algorithm development
- Surgical robotics control systems
- AI-assisted diagnostic support tools
- Global quality and regulatory strategy
Amgen’s Unprecedented Digital Scaling
Amgen’s participation in the GCC panel highlighted how even companies that came relatively late to the India GCC model are now scaling aggressively. The company’s Global Business Solutions center in Hyderabad is experiencing what executives described as “unprecedented scaling of digital capabilities and predictive analytics.”
Amgen, known for its biologics expertise and premium positioning in the pharmaceutical industry, is leveraging its Hyderabad center for:
- Advanced analytics supporting clinical development
- Digital twin modeling for biomanufacturing
- Patient outcome prediction using real-world evidence
- Commercial analytics and market access strategies
The company’s willingness to locate these sophisticated capabilities in India represents a significant shift from its historical operating model, where such functions were concentrated at U.S. headquarters or European centers.
Sanofi’s AI-First R&D Transformation
Sanofi’s announcement of GCC expansion plans at BioAsia 2026 included explicit focus on supporting “AI-first R&D and manufacturing transformation”—a positioning that places the India operations at the center of the company’s most strategic initiatives.
The French pharmaceutical giant has recognized that digital transformation in pharmaceutical R&D is not a incremental improvement but a fundamental reconceptualization of how drugs are discovered, developed, and manufactured. Positioning India operations as leaders in this transformation signals that expertise in AI, data science, and process analytics has become more strategically important than proximity to headquarters.
Sanofi’s Hyderabad business operations hub is now contributing to:
- AI-powered drug target identification
- Clinical trial design optimization
- Manufacturing process analytics
- Supply chain intelligence and forecasting
The “Digital Depth” Phenomenon
The recurring theme throughout the GCC panel was India’s “digital depth”—a capability that goes beyond the availability of engineers and data scientists to encompass ecosystem-level maturity in digital transformation.
Several factors contribute to this digital depth:
Talent Pool Breadth and Depth: India produces over 1.5 million STEM graduates annually, with significant concentrations in computer science, data science, and biotechnology. Hyderabad specifically has emerged as a magnet for this talent due to quality of life, cost of living, and concentration of premium employers.
Cross-Sector Digital Expertise: India’s IT services industry has been implementing digital transformations across sectors for decades. This creates a workforce that understands not just technology but how to implement it within complex organizational and regulatory contexts—a critical capability for pharmaceutical applications.
Cost-Effectiveness at Scale: While labor arbitrage is no longer the primary driver of GCC location decisions, the ability to hire PhD-level data scientists, experienced biotechnology professionals, and software engineers at 25-40% of U.S./European costs remains compelling—particularly for risk-intensive R&D where many programs will fail.
Time Zone Advantages: The India-U.S. time zone difference enables “follow-the-sun” development models where work progresses continuously. For clinical trial support, data analytics, and IT infrastructure, this provides substantial productivity gains.
Regulatory and IP Protection Maturity: India’s patent regime, data protection frameworks, and regulatory infrastructure have matured substantially, reducing concerns about IP security that previously constrained advanced R&D location decisions.
The LLM Revolution in Life Sciences: Novartis Case Study
Gail Horwood’s discussion of Novartis’s work on large language model (LLM)-based behavioral science tools provides a concrete example of the sophistication now present in India GCCs.
LLMs—the technology underlying ChatGPT and similar systems—are being adapted for healthcare-specific applications including:
- Patient education and engagement
- Healthcare provider decision support
- Clinical trial recruitment and retention
- Pharmacovigilance and adverse event detection
Building these systems requires not just technical AI expertise but deep understanding of:
- Healthcare workflows and clinician behavior
- Patient psychology and health literacy
- Regulatory constraints on medical claims and communications
- Integration with existing electronic health records and CRM systems
That Novartis is building these capabilities in Hyderabad for deployment in the U.S. market indicates confidence that the India team possesses the multidisciplinary expertise required—technical, clinical, regulatory, and commercial.
The Quality Management Innovation at Takeda
Takeda’s positioning of its Hyderabad GCC as a global leader in quality management systems represents another dimension of GCC evolution. Quality assurance and regulatory compliance have traditionally been highly centralized functions due to the catastrophic consequences of errors and the complexity of global regulatory requirements.
Takeda’s willingness to have Hyderabad lead development of global quality standards indicates that the center has achieved a level of regulatory sophistication and systems thinking that meets the company’s most demanding requirements. This includes:
- Development of Quality 4.0 frameworks incorporating AI and predictive analytics
- Global audit and inspection readiness protocols
- Regulatory intelligence and horizon scanning
- Training and capability building for worldwide operations
The “Digital Twin” Implementation
Multiple GCC representatives referenced the implementation of “digital twin” technology for biomanufacturing optimization—a capability that exemplifies the integration of deep process understanding with advanced analytics.
A digital twin is a virtual replica of a physical manufacturing process that can be used to:
- Model different process parameters and predict outcomes
- Simulate potential failure modes before they occur in actual production
- Optimize yield, quality, and cycle time
- Support regulatory submissions with in silico evidence
Building effective digital twins requires:
- Deep expertise in bioprocess engineering
- Advanced computational modeling capabilities
- Machine learning for parameter optimization
- Integration with actual manufacturing execution systems
That GCCs are leading this work demonstrates the evolution from “IT support” to “scientific innovation engine.”
The Ecosystem Effect: Why Hyderabad Specifically?
While multiple Indian cities host pharmaceutical and biotechnology GCCs, Hyderabad has emerged as the clear leader for life sciences specifically. Several ecosystem characteristics explain this concentration:
Anchor Institutions: The presence of the Centre for Cellular and Molecular Biology (CCMB), Indian Institute of Chemical Technology (IICT), and National Institute of Pharmaceutical Education and Research (NIPER) provides both talent and potential research collaboration.
Vaccine Capital Legacy: Hyderabad’s historical strength in vaccine manufacturing (Bharat Biotech, Biological E, Serum Institute operations) created a concentration of biologics expertise that multinational companies can leverage.
State Government Support: Telangana’s proactive life sciences policies, single-window clearances, and infrastructure investments have created a business-friendly environment specifically tailored to the sector.
Existing GCC Concentration: The presence of 600+ GCCs across sectors in Hyderabad creates network effects: talent availability, service provider ecosystem, quality of life amenities, and peer learning opportunities.
Cost-Quality Balance: While not the cheapest location in India, Hyderabad offers an optimal balance of talent quality, infrastructure reliability, and operational costs.
The Venture Capital and Startup Spillover
An underappreciated consequence of GCC concentration is the entrepreneurial spillover. Many innovative startups in Hyderabad are founded by former GCC employees who gained exposure to cutting-edge technologies and identified market opportunities.
This creates a virtuous cycle:
- GCCs train talent in advanced capabilities
- Experienced professionals leave to found startups
- Successful startups create acquisition or partnership opportunities for multinationals
- Multinationals strengthen GCCs to integrate acquired capabilities
- Strengthened GCCs attract more talent
The BioAsia 2026 Startup Pavilion showcased over 120 startups, many founded by professionals with GCC backgrounds. This entrepreneurial ecosystem enhances the overall attractiveness of Hyderabad as a life sciences hub.
Challenges and Limitations
Despite the overwhelmingly positive narrative, GCC representatives acknowledged persistent challenges:
Talent Retention at Senior Levels: While junior and mid-level talent is abundant, retaining senior scientists and executives who may prefer opportunities in the U.S. or Europe remains challenging.
Distance from Clinical Operations: For modalities that require close integration with clinical development, physical distance from major clinical trial sites can be limiting.
Regulatory Conservatism: Some regulatory authorities remain skeptical of work performed outside traditional pharmaceutical hubs, requiring additional validation.
Infrastructure Gaps: While improving, reliability of power, internet connectivity, and logistics infrastructure remains less consistent than in developed markets.
Time Zone Trade-offs: While enabling follow-the-sun work patterns, the time zone difference also creates challenges for real-time collaboration with global teams.
The Post-COVID Acceleration
Multiple panel participants noted that the COVID-19 pandemic accelerated the GCC evolution dramatically. When global travel became impossible and physical presence at headquarters was not feasible, companies were forced to empower distributed teams.
Many companies discovered that their India GCCs performed not just adequately but exceptionally during this period—managing critical projects, adapting to new ways of working, and maintaining productivity despite enormous external challenges.
This “forced experiment” in distributed operations broke down remaining skepticism about whether sophisticated R&D and strategic functions could be performed effectively from India. Companies that might have taken another decade to fully empower their GCCs compressed that evolution into 2-3 years.
Implications for the Global Industry Structure
The evolution of India’s GCCs from cost centers to innovation engines has profound implications for the global structure of the life sciences industry:
Knowledge Production Geography: Innovation is no longer geographically constrained to traditional hubs (Boston, San Francisco, Basel, Cambridge UK). Breakthroughs can originate anywhere with the right combination of talent and infrastructure.
Cost Structure Transformation: Companies that effectively leverage GCC capabilities can achieve 30-40% cost advantages in R&D while maintaining or improving quality—fundamentally altering competitive dynamics.
Talent Market Globalization: The most talented scientists and engineers increasingly have global opportunities, forcing companies and countries to compete on quality of life, intellectual challenge, and career growth rather than just compensation.
Supply Chain Resilience: Distributed R&D and manufacturing capabilities reduce vulnerability to regional disruptions—a lesson underscored by the pandemic.
“Integrated Extension” Model
Gail Horwood’s framing of the Hyderabad team as an “integrated extension of global teams” rather than a separate support unit encapsulates the evolved GCC model. In this paradigm:
- Teams in India are full participants in global project teams, not executing tasks assigned from elsewhere
- Innovation originates from multiple geographies simultaneously rather than flowing from headquarters outward
- Career paths include rotation between India and global locations, creating cultural integration
- Performance evaluation focuses on outcomes and impact rather than activity and process compliance
This model requires cultural transformation within multinational organizations—moving beyond legacy hierarchies where headquarters makes decisions and other locations implement them.
Policy Implications: Sustaining the Momentum
For India and Telangana to sustain and accelerate GCC evolution, several policy priorities emerged from the BioAsia discussions:
Talent Pipeline Investment: Continuous investment in STEM education, particularly programs that blend biological sciences with data science and AI.
Research Institution Linkages: Stronger connections between GCCs and academic research institutions to enable collaborative research and talent development.
Regulatory Modernization: Ensuring that Indian regulatory frameworks for data protection, IP rights, and clinical research align with global standards.
Infrastructure Reliability: Continued investment in power, connectivity, and transportation infrastructure to maintain competitiveness.
Quality of Life Enhancement: Investment in environmental quality, healthcare, education, and cultural amenities to retain senior talent who have global options.
The Indispensable Partner
The BioAsia 2026 GCC panel documented a transformation that few predicted even a decade ago: India has evolved from a cost-efficient location for routine pharmaceutical operations to an indispensable partner in global life sciences innovation.
Companies like Novartis, Takeda, Amgen, Olympus, and Sanofi are not merely maintaining India operations—they are strategically expanding them and entrusting them with their most critical digital and R&D transformations.
Hyderabad specifically has emerged as the clear leader in this evolution, combining biologics expertise, digital capabilities, supportive government policies, and ecosystem maturity.
The question facing multinational companies is no longer whether to have an India presence, but how to maximize strategic value from that presence. The question facing India and Telangana is whether they can sustain the policy consistency, infrastructure investment, and talent development required to maintain this position as other countries recognize the opportunity.
As Sanjay Patel of Takeda concluded: “India’s GCC evolution reflects a fundamental shift in how global companies think about innovation geography. We are witnessing the emergence of a truly multipolar life sciences innovation ecosystem, and India is one of the essential poles.”
The era of “outsourcing” is over. The era of “strategic partnership” has arrived. And Hyderabad is at its center.
– Sai Chaitanya Puligadda
